311 episodes

STAT’s weekly biotech podcast, breaking down the latest news, digging deep into industry goings-on, and giving you a preview of the week to come.

The Readout Loud STAT

    • Business
    • 4.6 • 289 Ratings

STAT’s weekly biotech podcast, breaking down the latest news, digging deep into industry goings-on, and giving you a preview of the week to come.

    309: Psychedelics at the FDA, ASCO recap, & MorphoSys update

    309: Psychedelics at the FDA, ASCO recap, & MorphoSys update

    STAT colleague Meghana Keshavan joins us to dissect Lykos Therapeutics' meeting with an FDA advisory committee. We also discuss the latest news in the health and life sciences, including stories from major biotech conferences.
    To learn more about Lykos' advisory committee meeting, go here; for more on the tumult at BIO, go here; for a recap of ASCO, go here; to read the latest on Novartis' acquisition of MorphoSys, go here. And you can sign up for Adam’s new newsletter, Biotech Scorecard, here.

    • 29 min
    308: An ASCO preview & another Duchenne trial failure

    308: An ASCO preview & another Duchenne trial failure

    We preview some of the research that will be presented at The American Society of Clinical Oncology conference in Chicago. We also discuss the latest news in the health and life sciences, including a milestone in lung disease R&D and a Duchenne muscular dystrophy confirmatory trial failure.  
    To read more about Merus' combination therapy, go here; For more on Johnson & Johnson's mixed data, click here; For more on Nippon Shinyaku's Duchenne drug trial failure, go here; To read more on Insmed's bronchiectasis treatment, click here; To sign up for STAT's ASCO newsletter, click here.

    • 28 min
    307: More tumult at BIO & coercive care for sickle cell patients

    307: More tumult at BIO & coercive care for sickle cell patients

    This week on “The Readout LOUD,” STAT's Chief Washington Correspondent Rachel Cohrs Zhang joins us to discuss the layoffs at trade group BIO and how things may be changing at the trade group. We also invite STAT reporter Eric Boodman on to talk about his new investigative series of stories exploring how Black women with sickle cell disease were coerced into getting sterilized.

    • 31 min
    306: Live! From the STAT Breakthrough Summit West

    306: Live! From the STAT Breakthrough Summit West

    On this week’s "Readout LOUD," we’re live in San Francisco at STAT’s Breakthrough Summit West. AI is a big theme this year, everywhere, so on that note, we chat with our AI correspondent — and recent Pulitzer finalist — Casey Ross, who sat down on stage to discuss AI-centered drug discovery with both NVIDIA and Google-backed Isomorphic Labs.
    We also discuss this week’s biotech news, including yet more obesity drug data, this time from Roche, and the closing of Novartis’ acquisition of MorphoSys.

    • 23 min
    305: Everything you need to know about H5N1 bird flu

    305: Everything you need to know about H5N1 bird flu

    This week on "The Readout LOUD," STAT senior infectious diseases reporter Helen Branswell walks us through ongoing H5N1 outbreak in the U.S. and issues with monitoring the spread. And in a bit of shameless self-promotion, we’ll talk to our colleagues Bob Herman and Casey Ross about being named Pulitzer finalists in investigative reporting for their reporting on United Healthcare’s use of algorithms in coverage decisions. We'll hear what’s happened since their explosive work was published last year.

    • 31 min
    304: Controversial brain tissue research, obesity drug sales and Novartis’ M&A drama

    304: Controversial brain tissue research, obesity drug sales and Novartis’ M&A drama

    The removal of small amounts of brain tissue from desperately ill patients, done as part of a Mount Sinai research project, triggered alarm bells at the Food and Drug Administration and has raised broader questions about the scientific and ethical justification for live-brain research. Journalist and STAT contributor Katherine Eban joins “The Readout LOUD” podcast to discuss the results of a two-year investigation. We also discuss Novartis’ effort to acquire MorphoSys, and the latest news on Eli Lilly and Novo Nordisk’s blockbuster obesity drugs with Elaine Chen, the newest member of STAT’s biotech reporting team.

    • 33 min

Customer Reviews

4.6 out of 5
289 Ratings

289 Ratings

C4l71n ,

Great Podcast

Amazing content — the podcast hosts really understand the biopharma field (both the science and history) and their jokes are also quite funny.

dharma matt ,

Generally good

I like their summaries it keeps me in the loop. But boy were they clueless on all things Covid and really did society a disservice by being a mouthpiece for public health instead of challenging obviously bad policy. Hope they do an introspective review one day and come clean

WndyG ,

Good but could be better

This podcast does a good job of tackling developments in Biotech and boiling down complex subjects into cliff notes versions for listeners who want to get a quick overview of what is happening in the industry. The hosts are smart and entertaining but can be overly judgmental and “know-it-alls” in their commentary. After all, they are reporting on brilliant innovation and amazing science, not actually creating brilliant innovation and amazing science.

Top Podcasts In Business

The Ramsey Show
Ramsey Network
REAL AF with Andy Frisella
Andy Frisella #100to0
Money Rehab with Nicole Lapin
Money News Network
Young and Profiting with Hala Taha
Hala Taha | YAP Media Network
The Money Mondays
Dan Fleyshman
The Diary Of A CEO with Steven Bartlett
DOAC

You Might Also Like

The Long Run with Luke Timmerman
Timmerman Report
Business Of Biotech
Matt Pillar
BioCentury This Week
BioCentury
Raising Health
Andreessen Horowitz
Biotech Hangout
Daphne Zohar, Josh Schimmer, Brad Loncar, Tim Opler & more
a16z Podcast
Andreessen Horowitz